Dual acting cd1d immunoglobulin for treatment of myelodysplastic syndromes

Abstract

The present disclosure provides multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR, pharmaceutical preparations and use of such multi-specific binding moieties and/or immunoglobulins in the treatment of a myelodysplastic syndrome.

1 . A method of treating a myelodysplastic syndrome in a subject in need thereof comprising administering to the subject:
 a multispecific antibody comprising a first binding domain that specifically binds to human CD1d and a second binding domain that specifically binds to a Vγ9Vδ2 T cell receptor.   
     
     
         2 . The method of  claim 1 , further comprising administering a low-dose of IL-2 of less than 2 MIU/day. 
     
     
         3 . The method of  claim 1 , wherein the first antigen binding domain comprises SEQ ID NO: 11 or 12. 
     
     
         4 . The method of  claim 1 , wherein the second antigen binding domain comprises SEQ ID NO: 5, 6, or 7. 
     
     
         5 . The method of  claim 1 , wherein the multispecific antibody comprises an amino acid sequence of SEQ ID NO: 13 or 14. 
     
     
         6 . The method of  claim 1 , wherein the subject has received prior treatment with at least one hypomethylating agent.